Welcome to our dedicated page for iHuman SEC filings (Ticker: IH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
iHuman Inc. filings document its foreign-issuer reporting as a China-based provider of tech-powered intellectual development products whose American depositary shares represent Class A ordinary shares. Current reports on Form 6-K furnish press releases on quarterly and annual results, including revenue, gross profit, operating income, net income, average total MAUs, deferred revenue, and customer advances.
The company’s regulatory record also includes annual Form 20-F reporting and related ADS disclosures. These filings address the company’s product portfolio, subscription and content-driven business model, dividend actions, governance framework, capital structure, and risk disclosures for its apps, interactive content, smart devices, and China-centered operations.
iHuman Inc. director Chi Hanfeng has filed an initial ownership report showing holdings of stock options linked to the company’s Class A ordinary shares. The filing lists options covering 27,000 underlying shares at an exercise price of $0.0500 per share, expiring on November 30, 2030, and another block covering 27,000 underlying shares at the same exercise price, expiring on December 15, 2032.
According to the footnotes, the 2030 options were granted on November 30, 2020 and vested over three years, while the 2032 options were granted on December 15, 2022 and vest in equal annual installments over four years. All holdings are reported as directly owned.
iHuman Inc. director Li Xuenan reported existing option holdings in a Form 3. The filing shows two option grants, each covering 27,000 underlying Class A ordinary shares at an exercise price of 0.0500 per share. One grant expires on November 30, 2030 and fully vested by October 8, 2023. The second grant expires on December 15, 2032 and vests in four equal annual installments after its December 15, 2022 grant date.
iHuman Inc. director and Chief Financial Officer Wang Weiwei filed an initial ownership report listing existing equity awards and holdings. The filing shows stock options over 2,200,000 and 520,000 underlying Class A ordinary shares at an exercise price of $0.0500 per share, plus 200,000 American Depositary Shares held indirectly through the issuer's ESOP platform. Footnotes explain that each ADS represents five Class A ordinary shares and that one option grant from December 15, 2022 vests over four years through December 15, 2026.